CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients
A fixed one-year course of two targeted drugs kept CLL under control far longer than chemo-immunotherapy, and most patients had no detectable disease when treatment stopped.
CLL14 randomised 432 previously untreated patients with CLL and coexisting conditions (CIRS score above 6 or creatinine clearance under 70 mL/min) to 12 cycles of venetoclax plus obinutuzumab or chlorambucil plus obinutuzumab. The primary endpoint was investigator-assessed progression-free survival. At 24 months PFS was 88.2% versus 64.1% (hazard ratio 0.35), and undetectable MRD in peripheral blood three months after treatment ended was 75.5% versus 35.2%. Grade 3-4 neutropenia and infections were similar between arms. With six years of follow-up more than half of venetoclax-obinutuzumab patients remained progression-free against roughly a fifth on chemo-immunotherapy, though overall survival was not significantly different.
- 432 patients with untreated CLL and comorbidities; 12 cycles of venetoclax-obinutuzumab vs chlorambucil-obinutuzumab.
- 24-month PFS 88.2% vs 64.1%; hazard ratio 0.35.
- Undetectable MRD (below 10^-4) in blood 3 months after treatment end: 75.5% vs 35.2%.
- Grade 3-4 neutropenia 52.8% vs 48.1%; grade 3-4 infections 17.5% vs 15.0%.
- Benefit held across IGHV-unmutated and TP53-aberrant subgroups, though del(17p)/TP53 patients relapsed earlier.
CLL14 established the first chemotherapy-free, fixed-duration regimen for front-line CLL and made MRD-guided thinking mainstream in the disease. Patients get a year of treatment and then a treatment-free period rather than indefinite therapy. The choice today is between fixed-duration venetoclax combinations and continuous BTK inhibitors, with no proven survival difference.
- Overall survival has not differed significantly, partly because effective salvage therapies exist.
- Patients were older and less fit; CLL13/GAIA later confirmed benefit in fit patients.
- Venetoclax requires a 5-week ramp-up and tumour-lysis monitoring, which is a practical burden.
- Retreatment strategy after relapse was not defined by the trial.